Pharmacokinetics and Pharmacodynamics in Drug Registration - E-Learning Module

  • ID: 3699431
  • Training
  • Region: Global
  • 210 Minutes
  • Zenosis Limited
1 of 2
Explain the Role of PK/PD Studies in Modern Drug Development and Registration
Pharmacokinetic and pharmacodynamic (PK/PD) studies play a vital role in drug development. Regulatory authorities are placing greater emphasis on the role of PK/PD in drug registration. This module enables the learner to understand the role of PK/PD data in establishing the safety profile of a new or generic product.

Who will benefit from this module?

Pharmacologists, nonclinical and clinical researchers, and others involved in drug development will find this module an accessible, concise account of the relevance of PK & PD in the registration of drugs for human use. A basic knowledge of the terminology of PK and PD is assumed.

Learning objectives:

- Explain the role of PK/PD studies in modern drug development and registration.
- Describe the use of PK/PD data from preclinical and clinical studies.
- Recognise the role of PK parameters in special population studies.
- Identify the processes used to obtain PK/PD data from nonclinical and clinical trials.
- Describe the PK/PD factors underpinning the concepts of bioavailability and bioequivalence.

Module outline

CPD Points: 3.5

Assessment: Multiple-choice mastery assessment
Note: Product cover images may vary from those shown
2 of 2
PK/PD role and relevance - The role and relevance of PK and PD in the registration of new and generic drugs is described. The emerging trend towards formal standardisation of PK studies is discussed.

PK/PD studies in drug development - The role of PK/PD studies in nonclinical and clinical studies is explained. Study designs are discussed. Bioavailability, ADME and toxicokinetic studies are described. A variety of clinical studies are outlined in the context of PK.

Drug administration routes - Time-concentration curves for various routes of administration are compared. Prediction of the best route, on the basis of PK data, is discussed.

PD for drug registration - The distinction between PD effects and clinical outcomes is explained. Examples of dose-response curves and their interpretations are given. The importance of dose-response relationships in clinical trials and drug registration is discussed.

Sampling practice and outcomes - Common PK variables derived from sampling are described. Good sampling practice is discussed.

Data analysis - Compartmental and non-compartmental analysis are compared. Uses of AUC and volume of distribution are described.

Special populations - Requirements for studies in populations such as those with liver or kidney dysfunction are described.

Generics and bioequivalence - The principles and practice of bioequivalence studies for the registration of generic products are described.
Note: Product cover images may vary from those shown
3 of 2


4 of 2
Note: Product cover images may vary from those shown